tetano
Editor, Senior Moderator
Prev Med
. 2021 Oct 20;153:106860.
doi: 10.1016/j.ypmed.2021.106860. Online ahead of print.
Symptomology following mRNA vaccination against SARS-CoV-2
Joseph E Ebinger[SUP] 1 [/SUP], Roy Lan[SUP] 2 [/SUP], Nancy Sun[SUP] 1 [/SUP], Min Wu[SUP] 1 [/SUP], Sandy Joung[SUP] 1 [/SUP], Gregory J Botwin[SUP] 3 [/SUP], Patrick Botting[SUP] 1 [/SUP], Daniah Al-Amili[SUP] 4 [/SUP], Harriet Aronow[SUP] 5 [/SUP], James Beekley[SUP] 6 [/SUP], Bernice Coleman[SUP] 5 [/SUP], Sandra Contreras[SUP] 6 [/SUP], Wendy Cozen[SUP] 7 [/SUP], Jennifer Davis[SUP] 3 [/SUP], Philip Debbas[SUP] 3 [/SUP], Jacqueline Diaz[SUP] 1 [/SUP], Matthew Driver[SUP] 1 [/SUP], Justyna Fert-Bober[SUP] 8 [/SUP], Quanquan Gu[SUP] 9 [/SUP], Mallory Heath[SUP] 1 [/SUP], Ergueen Herrera[SUP] 6 [/SUP], Amy Hoang[SUP] 1 [/SUP], Shehnaz K Hussain[SUP] 6 [/SUP], Carissa Huynh[SUP] 10 [/SUP], Linda Kim[SUP] 5 [/SUP], Michelle Kittleson[SUP] 1 [/SUP], Yunxian Liu[SUP] 1 [/SUP], John Lloyd[SUP] 1 [/SUP], Eric Luong[SUP] 1 [/SUP], Bhavya Malladi[SUP] 1 [/SUP], Akil Merchant[SUP] 11 [/SUP], Noah Merin[SUP] 12 [/SUP], Angela Mujukian[SUP] 3 [/SUP], Nathalie Nguyen[SUP] 6 [/SUP], Trevor-Trung Nguyen[SUP] 1 [/SUP], Valeriya Pozdnyakova[SUP] 3 [/SUP], Mohamad Rashid[SUP] 1 [/SUP], Koen Raedschelders[SUP] 13 [/SUP], Karen L Reckamp[SUP] 6 [/SUP], Kylie Rhoades[SUP] 1 [/SUP], Sarah Sternbach[SUP] 1 [/SUP], Rocío Vallejo[SUP] 1 [/SUP], Shane White[SUP] 3 [/SUP], Rose Tompkins[SUP] 1 [/SUP], Melissa Wong[SUP] 14 [/SUP], Moshe Arditi[SUP] 15 [/SUP], Jane C Figueiredo[SUP] 6 [/SUP], Jennifer E Van Eyk[SUP] 8 [/SUP], Peggy B Miles[SUP] 16 [/SUP], Cynthia Chavira[SUP] 11 [/SUP], Rita Shane[SUP] 17 [/SUP], Kimia Sobhani[SUP] 18 [/SUP], Gil Y Melmed[SUP] 3 [/SUP], Dermot P B McGovern[SUP] 3 [/SUP], Jonathan G Braun[SUP] 19 [/SUP], Susan Cheng[SUP] 20 [/SUP], Margo B Minissian[SUP] 21 [/SUP]
Affiliations
Abstract
Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P < 0.001), with >80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19-2.51) and dose 2 (1.76, 1.28-2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last <2 days. Appreciable post-vaccine symptoms are associated with female sex, prior COVID-19, younger age, and hypertension. This information can aid clinicians in advising patients on the safety and expected symptomatology associated with vaccination.
Keywords: SARS-CoV-2; Vaccination; Vaccine-associated symptoms.
. 2021 Oct 20;153:106860.
doi: 10.1016/j.ypmed.2021.106860. Online ahead of print.
Symptomology following mRNA vaccination against SARS-CoV-2
Joseph E Ebinger[SUP] 1 [/SUP], Roy Lan[SUP] 2 [/SUP], Nancy Sun[SUP] 1 [/SUP], Min Wu[SUP] 1 [/SUP], Sandy Joung[SUP] 1 [/SUP], Gregory J Botwin[SUP] 3 [/SUP], Patrick Botting[SUP] 1 [/SUP], Daniah Al-Amili[SUP] 4 [/SUP], Harriet Aronow[SUP] 5 [/SUP], James Beekley[SUP] 6 [/SUP], Bernice Coleman[SUP] 5 [/SUP], Sandra Contreras[SUP] 6 [/SUP], Wendy Cozen[SUP] 7 [/SUP], Jennifer Davis[SUP] 3 [/SUP], Philip Debbas[SUP] 3 [/SUP], Jacqueline Diaz[SUP] 1 [/SUP], Matthew Driver[SUP] 1 [/SUP], Justyna Fert-Bober[SUP] 8 [/SUP], Quanquan Gu[SUP] 9 [/SUP], Mallory Heath[SUP] 1 [/SUP], Ergueen Herrera[SUP] 6 [/SUP], Amy Hoang[SUP] 1 [/SUP], Shehnaz K Hussain[SUP] 6 [/SUP], Carissa Huynh[SUP] 10 [/SUP], Linda Kim[SUP] 5 [/SUP], Michelle Kittleson[SUP] 1 [/SUP], Yunxian Liu[SUP] 1 [/SUP], John Lloyd[SUP] 1 [/SUP], Eric Luong[SUP] 1 [/SUP], Bhavya Malladi[SUP] 1 [/SUP], Akil Merchant[SUP] 11 [/SUP], Noah Merin[SUP] 12 [/SUP], Angela Mujukian[SUP] 3 [/SUP], Nathalie Nguyen[SUP] 6 [/SUP], Trevor-Trung Nguyen[SUP] 1 [/SUP], Valeriya Pozdnyakova[SUP] 3 [/SUP], Mohamad Rashid[SUP] 1 [/SUP], Koen Raedschelders[SUP] 13 [/SUP], Karen L Reckamp[SUP] 6 [/SUP], Kylie Rhoades[SUP] 1 [/SUP], Sarah Sternbach[SUP] 1 [/SUP], Rocío Vallejo[SUP] 1 [/SUP], Shane White[SUP] 3 [/SUP], Rose Tompkins[SUP] 1 [/SUP], Melissa Wong[SUP] 14 [/SUP], Moshe Arditi[SUP] 15 [/SUP], Jane C Figueiredo[SUP] 6 [/SUP], Jennifer E Van Eyk[SUP] 8 [/SUP], Peggy B Miles[SUP] 16 [/SUP], Cynthia Chavira[SUP] 11 [/SUP], Rita Shane[SUP] 17 [/SUP], Kimia Sobhani[SUP] 18 [/SUP], Gil Y Melmed[SUP] 3 [/SUP], Dermot P B McGovern[SUP] 3 [/SUP], Jonathan G Braun[SUP] 19 [/SUP], Susan Cheng[SUP] 20 [/SUP], Margo B Minissian[SUP] 21 [/SUP]
Affiliations
- PMID: 34687733
- PMCID: PMC8527734
- DOI: 10.1016/j.ypmed.2021.106860
Abstract
Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P < 0.001), with >80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19-2.51) and dose 2 (1.76, 1.28-2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last <2 days. Appreciable post-vaccine symptoms are associated with female sex, prior COVID-19, younger age, and hypertension. This information can aid clinicians in advising patients on the safety and expected symptomatology associated with vaccination.
Keywords: SARS-CoV-2; Vaccination; Vaccine-associated symptoms.